NCT00075010View on ClinicalTrials.gov

Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 23, 2004

Primary Completion Date

November 8, 2006

Study Completion Date

November 8, 2006

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Decitabine

15 mg/m\^2 by vein over 1 hour times 10 days

DRUG

Valproic acid

20 mg/kg given orally daily for 10 days

Trial Locations (1)

77030

M.D. Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00075010 - Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter